# Evidence-based dental management strategies for individuals with congenital hemophilia: a systematic review

**Authors:** Mathangi Kumar, Sulochana Badagabettu, Keerthilatha M Pai, Linu Sara George

PMC · DOI: 10.1186/s12903-026-07736-6 · BMC Oral Health · 2026-01-30

## TL;DR

This paper reviews dental care strategies for people with hemophilia, focusing on how clotting factor treatments are used during various dental procedures.

## Contribution

The study systematically evaluates dental procedures and clotting factor regimens for hemophilia patients of different severities.

## Key findings

- Routine dental care like restoration and scaling can be safely performed with proper factor correction.
- Dental extractions with local anesthesia are safer than nerve blocks, which require prior clotting factor administration.
- Anti-fibrinolytics like EACA and tranexamic acid reduce the need for additional clotting factor infusions.

## Abstract

People with hemophilia commonly present with a range of bleeding symptoms, from minor oral cavity bleeds to life-threatening events such as intracranial hemorrhage. People with hemophilia often exhibit poor oral health, attributed to disease-specific barriers and a fear of dental procedures, which may exacerbate their oral disease burden. This systematic review aimed to evaluate the various dental procedures performed in patients with hemophilia and the corresponding clotting factor concentrate replacement regimens used for individuals with mild, moderate, and severe forms of the disease.

An electronic database search was carried out using MEDLINE by PubMed, Scopus, Google Scholar, Web of Science, ProQuest, CINAHL, EBSCO Dental collection and EMBASE databases from inception to March 2025 for studies published in English language. The search strategy terms included were “hemophilia A”, “hemophilia A”, “hemophilia B”, “hemophilia B”, “dental care”, “oral surgery”, “complications”, “bleeding”. Case control studies, randomized controlled trials, observational studies and case reports addressing the dental treatments for people with hemophilia A/hemophilia B were included. Cases of acquired hemophilia and cases of hemophilia who are inhibitor positive were excluded.

A total of 23 studies were included for the final review. Majority of the studies have ensured to achieve 30% to 50% factor correction for dental procedures. Routine dental care procedures like restoration and dental scaling with the necessary technical specifications can be safely performed. Dental extractions can be safely performed using local infiltration anesthesia; however, administering nerve blocks typically necessitates prior administration of clotting factors due to the elevated bleeding risk. Adjuvant systemic anti-fibrinolytics like Epsilon-aminocaproic acid (EACA) and tranexamic acid greatly reduces the need for additional factor infusion.

The use of prophylactic clotting factors during dental interventions in hemophilia patients showed notable inconsistencies across studies. This inconsistency underscores the importance of conducting larger, prospective clinical studies to better understand the rationale behind clotting factor use and its effects on dental treatment outcomes in patients with varying degrees of hemophilia severity.

The online version contains supplementary material available at 10.1186/s12903-026-07736-6.

## Linked entities

- **Chemicals:** Epsilon-aminocaproic acid (PubChem CID 564), tranexamic acid (PubChem CID 5526)
- **Diseases:** hemophilia A (MONDO:0010602), hemophilia B (MONDO:0010604)

## Full-text entities

- **Diseases:** congenital hemophilia (MESH:D006467)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12930792/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12930792/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12930792/full.md

---
Source: https://tomesphere.com/paper/PMC12930792